AbbVie

• 

  10/3/2024

  **AbbVie: Breakthroughs in Neurology & Oncology**

• 10/2/2024

  **AbbVie: $200 Peak Rating Downgraded**

• 9/29/2024

  **AbbVie: Valuation Risks Ahead**